Zenas BioPharma, Inc. Price & Performance (ZBIO)

Zenas BioPharma has appointed Dr. Lisa von Moltke as its new Head of Research and Development and Chief Medical Officer. With over three decades of expertise in drug development, Dr. von Moltke is expected to play a pivotal role in advancing the company’s autoimmune disease therapies.12

The Rosen Law Firm is investigating potential legal claims on behalf of investors in Nike NFTs issued by RTFKT, Inc. Following RTFKT's operational wind-down, investors may seek compensation through a class action. The move highlights the legal risks tied to emerging crypto assets.3

Zenas BioPharma has received an "outperform" rating from Wedbush, citing the promising safety profile of its lead therapy, obexelimab. The company’s ongoing trials targeting autoimmune diseases have positioned it as a potential leader in the biopharma sector, with analysts projecting significant growth.45